Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Psychostimulant treatment and the developing cortex in attention deficit hyperactivity disorder.

Shaw P, Sharp WS, Morrison M, Eckstrand K, Greenstein DK, Clasen LS, Evans AC, Rapoport JL.

Am J Psychiatry. 2009 Jan;166(1):58-63. doi: 10.1176/appi.ajp.2008.08050781. Epub 2008 Sep 15.

2.

The use of psychostimulants in the pediatric patient.

Pliszka SR.

Pediatr Clin North Am. 1998 Oct;45(5):1085-98. Review.

PMID:
9884676
3.

[Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD].

Ludolph AG, Kölch M, Plener PL, Schulze UM, Spröber N, Fegert JM.

Z Kinder Jugendpsychiatr Psychother. 2009 Sep;37(5):405-11. doi: 10.1024/1422-4917.37.5.405. Review. German.

PMID:
19739058
4.

[The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].

Frölich J, Banaschewski T, Spanagel R, Döpfner M, Lehmkuhl G.

Z Kinder Jugendpsychiatr Psychother. 2012 Sep;40(5):287-99; quiz 299-300. doi: 10.1024/1422-4917/a000185. German.

PMID:
22869222
5.

Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder.

Findling RL, Short EJ, Manos MJ.

J Am Acad Child Adolesc Psychiatry. 2001 Dec;40(12):1441-7.

PMID:
11765290
6.

Cortical development in typically developing children with symptoms of hyperactivity and impulsivity: support for a dimensional view of attention deficit hyperactivity disorder.

Shaw P, Gilliam M, Liverpool M, Weddle C, Malek M, Sharp W, Greenstein D, Evans A, Rapoport J, Giedd J.

Am J Psychiatry. 2011 Feb;168(2):143-51. doi: 10.1176/appi.ajp.2010.10030385. Epub 2010 Dec 15.

7.

Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder.

Fone KC, Nutt DJ.

Curr Opin Pharmacol. 2005 Feb;5(1):87-93. Review.

PMID:
15661631
8.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
9.

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.

Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H.

J Clin Psychiatry. 2005 Feb;66(2):253-9.

PMID:
15705013
10.
11.

Psychopharmacology of ADHD: children and adolescents.

Findling RL, Dogin JW.

J Clin Psychiatry. 1998;59 Suppl 7:42-9. Review.

12.

Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies.

Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, Faraone SV, Biederman J.

J Clin Psychiatry. 2013 Sep;74(9):902-17. doi: 10.4088/JCP.12r08287. Review.

13.

Longitudinal mapping of cortical thickness and clinical outcome in children and adolescents with attention-deficit/hyperactivity disorder.

Shaw P, Lerch J, Greenstein D, Sharp W, Clasen L, Evans A, Giedd J, Castellanos FX, Rapoport J.

Arch Gen Psychiatry. 2006 May;63(5):540-9.

PMID:
16651511
14.

Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system?

Gerlach M, Grünblatt E, Lange KW.

Atten Defic Hyperact Disord. 2013 Jun;5(2):71-81. doi: 10.1007/s12402-013-0105-y. Epub 2013 Apr 21. Review.

PMID:
23605387
15.

Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.

Schulz KP, Fan J, Bédard AC, Clerkin SM, Ivanov I, Tang CY, Halperin JM, Newcorn JH.

Arch Gen Psychiatry. 2012 Sep;69(9):952-61. doi: 10.1001/archgenpsychiatry.2011.2053.

PMID:
22945622
16.

Response to growth hormone in attention deficit hyperactivity disorder: effects of methylphenidate and pemoline therapy.

Rao JK, Julius JR, Breen TJ, Blethen SL.

Pediatrics. 1998 Aug;102(2 Pt 3):497-500.

PMID:
9685452
17.

Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.

Olfson M, Huang C, Gerhard T, Winterstein AG, Crystal S, Allison PD, Marcus SC.

J Am Acad Child Adolesc Psychiatry. 2012 Feb;51(2):147-56. doi: 10.1016/j.jaac.2011.11.008. Epub 2011 Dec 20.

18.

Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR.

J Child Adolesc Psychopharmacol. 2009 Oct;19(5):501-10. doi: 10.1089/cap.2008.0152.

19.

Psychotic side effects of psychostimulants: a 5-year review.

Cherland E, Fitzpatrick R.

Can J Psychiatry. 1999 Oct;44(8):811-3.

PMID:
10566114
20.

Altered cortical morphology in sensorimotor processing regions in adolescents and adults with attention-deficit/hyperactivity disorder.

Duerden EG, Tannock R, Dockstader C.

Brain Res. 2012 Mar 22;1445:82-91. doi: 10.1016/j.brainres.2012.01.034. Epub 2012 Jan 24.

PMID:
22325095

Supplemental Content

Support Center